Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12678284 | 1.00 | PAOX (0.55) | PAOXCYP1A2TDP1ALDH1A1TSHR | |
| SCHEMBL12856593 | 0.91 | PAOX (0.48) | PAOXCYP1A2TDP1ALDH1A1TSHR | |
| SCHEMBL19196092 | 0.91 | PAOX (0.48) | PAOXCYP1A2TDP1ALDH1A1TSHR | |
| SCHEMBL17032498 | 0.91 | PAOX (0.48) | PAOXCYP1A2TDP1ALDH1A1TSHR | |
| SCHEMBL12735367 | 0.91 | SIGMAR1 (0.56) | PAOXCYP1A2TDP1ALDH1A1TSHR | |
| SCHEMBL13527664 | 0.89 | NPSR1 (0.46) | PAOXTDP1ALDH1A1KDM4EKMT2A | |
| SCHEMBL13165521 | 0.89 | NPSR1 (0.46) | PAOXTDP1ALDH1A1KDM4EKMT2A | |
| SCHEMBL8060957 | 0.89 | NPSR1 (0.46) | PAOXTDP1ALDH1A1KDM4EKMT2A | |
| SCHEMBL12909322 | 0.89 | — | — | |
| SCHEMBL13198760 | 0.86 | PAOX (0.47) | PAOXCYP1A2TDP1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 337 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024068848-A1 | METHODS FOR TREATING OBESITY | ZEALAND PHARMA A/S (DK) | 2024-04-04 | — | — | WO | disclosed |
| US-11858916-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2024-01-02 | — | — | US | disclosed |
| WO-2023250513-A1 | 13-MEMBERED MACROLIDE COMPOUNDS FOR TREATING DISEASES MEDIATED BY ABNORMAL PROTEIN TRANSLATION | ZIKANI THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20230357249-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | UNIV MICHIGAN REGENTS (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| EP-4198031-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | Merck Patent GmbH (DE) | 2023-06-21 | — | — | EP | disclosed |
| WO-2023093728-A1 | BRM SELECTIVE DEGRADATION AGENT COMPOUND AND USE THEREOF | 江苏先声药业有限公司 | 2023-06-01 | — | — | WO | disclosed |
| WO-2023097038-A1 | CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | FULL-LIFE TECHNOLOGIES U.S. INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| US-20230143604-A1 | QW DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-11 | — | — | US | disclosed |
| WO-2023077129-A1 | TETRAZINE CONJUGATES FOR IN VIVO TARGETED DELIVERY OF A PAYLOAD | TAMBO, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |
| WO-2007058989-A2 | QUINAZOLINES USEFUL AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070112043-A1 | Acylated and non-acylated imidazo[2,1-b]-1,3,4,-thiadiazole-2-sulfonamides, and uses thereof | AEGERA THERAPEUTICS, INC. (CA) | 2007-05-17 | — | — | US | disclosed |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070099956-A1 | Nitrogen-containing heterocyclic derivatives having 2, 6-disubstituted styryl | ASTELLAS PHARMA INC. AND KOTOBUKI PHARMACEUTICAL CO., LTD. | 2007-05-03 | — | — | US | disclosed |
| US-20070099956-A1 | Nitrogen-containing heterocyclic derivatives having 2, 6-disubstituted styryl | ASTELLAS PHARMA INC. AND KOTOBUKI PHARMACEUTICAL CO., LTD. | 2007-05-03 | — | — | US | disclosed |
| US-20070060569-A1 | Azacycloalkyl substituted acetic acid derivatives for use as MMP inhibitors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
| US-20070060569-A1 | Azacycloalkyl substituted acetic acid derivatives for use as MMP inhibitors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
| US-20070042952-A1 | Analogues of glp-1 | IPSEN PHARMA S.A.S. (FR) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | PAOX 3123/4885CYP1A2 4437/4885TDP1 105/4885 |
| US-20230357249-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | AR, GPER1, CRBN | PAOX 1519/4885CYP1A2 169/4885TDP1 3330/4885 |
| US-20230143604-A1 | QW DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | GIPR, GLP1R, GRPR | PAOX 3171/4885CYP1A2 4255/4885TDP1 4318/4885 |
| US-20070112043-A1 | Acylated and non-acylated imidazo[2,1-b]-1,3,4,-thiadiazole-2-sulfonamides, and uses thereof | AADAC, NAT1, PMP22 | PAOX 428/4885CYP1A2 761/4885TDP1 1265/4885 |
| US-20070042952-A1 | Analogues of glp-1 | GLP1R, IAPP, GIPR | PAOX 2991/4885CYP1A2 4732/4885TDP1 2492/4885 |
| US-20070060569-A1 | Azacycloalkyl substituted acetic acid derivatives for use as MMP inhibitors | MMP9, MMP1, MMP13 | PAOX 532/4885CYP1A2 268/4885TDP1 3774/4885 |
| US-11858916-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | PAOX 1928/4885CYP1A2 3183/4885TDP1 3599/4885 |
| US-20070099956-A1 | Nitrogen-containing heterocyclic derivatives having 2, 6-disubstituted styryl | SCN1B, CACNA1B, SCN2A | PAOX 4139/4885CYP1A2 3344/4885TDP1 2861/4885 |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | ADORA2A, ADORA3, ADORA1 | PAOX 3050/4885CYP1A2 1973/4885TDP1 2324/4885 |
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | BMX, ERBB2, FRK | PAOX 3326/4885CYP1A2 3426/4885TDP1 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.